Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm ...

BASKING RIDGE, N.J. & RAHWAY, N.J., August 06, 2024--Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global co ...

BASKING RIDGE, N.J. & RAHWAY, N.J., August 06, 2024--Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck, Daiichi Sankyo Add Merck's MK-6070 to Collaboration Provided by Dow Jones Aug 6, 2024, 12:00:00 PM. By Colin Kellaher . Merck & Co. and Daiichi Sankyo are expanding their global ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that they have added another experimental therapy to their recent partnership, which targeted a class of cancer drugs known as ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ...

Merck & Co – known as MSD outside the US and Canada – is set to receive $170m upfront from Daiichi Sankyo to jointly develop and commercialise its investigational T-cell engager, MK-6070. The deal ...